The proteasome and proteasome inhibitors in multiple myeloma
S Gandolfi, JP Laubach, T Hideshima… - Cancer and Metastasis …, 2017 - Springer
Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …
the treatment of multiple myeloma in the past two decades, and now form one of the …
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
D Niewerth, G Jansen, YG Assaraf, S Zweegman… - Drug resistance …, 2015 - Elsevier
Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a
cornerstone position in the treatment of hematological malignancies, particularly multiple …
cornerstone position in the treatment of hematological malignancies, particularly multiple …
Recent contributions of quinolines to antimalarial and anticancer drug discovery research
T Van de Walle, L Cools, S Mangelinckx… - European Journal of …, 2021 - Elsevier
Quinoline, a privileged scaffold in medicinal chemistry, has always been associated with a
multitude of biological activities. Especially in antimalarial and anticancer research …
multitude of biological activities. Especially in antimalarial and anticancer research …
[HTML][HTML] Soluble and cell–cell-mediated drivers of proteasome inhibitor resistance in multiple myeloma
ML Farrell, MR Reagan - Frontiers in endocrinology, 2018 - frontiersin.org
It is becoming clear that myeloma cell-induced disruption of the highly organized bone
marrow components (both cellular and extracellular) results in destruction of the marrow and …
marrow components (both cellular and extracellular) results in destruction of the marrow and …
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
D Niewerth, GJL Kaspers, G Jansen… - Journal of hematology & …, 2016 - Springer
Background Drug combinations of the proteasome inhibitor bortezomib with cytotoxic
chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric …
chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric …
Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines
S Hu, Y Jin, Y Liu, M Ljungman, N Neamati - European journal of medicinal …, 2018 - Elsevier
Inhibition of proteasome activity blocks the degradation of dysfunctional proteins and
induces cancer cell death due to cellular stress. Thus, proteasome inhibitors represent an …
induces cancer cell death due to cellular stress. Thus, proteasome inhibitors represent an …
Non-peptidic natural products as ubiquitin-proteasome inhibitors
S Sengupta, G Mehta - Tetrahedron, 2019 - Elsevier
Approval of bortezomib has validated ubiquitin-proteasome pathway as an important target
for treatment of haematological malignancies. However, clinical shortcomings of bortezomib …
for treatment of haematological malignancies. However, clinical shortcomings of bortezomib …
[图书][B] Health Sciences Internal Sciences
AK KADİROĞLU - 2018 - books.google.com
Page 1 akademisyenyayinevi akademisyen com ONLİNE SİPARİŞ AKADEMİSYEN
KİTABEVİ Halk Sokak No: 5/A Sıhhıye-Yenişehir/ANKARA 9 786052 580578 Tel: 0312 431 …
KİTABEVİ Halk Sokak No: 5/A Sıhhıye-Yenişehir/ANKARA 9 786052 580578 Tel: 0312 431 …
Dynamics of Ubiquitin-Conjugate Population in Response to Inhibition of Ubiquitin-Proteasome Pathway
JJ Minissale - 2018 - search.proquest.com
The goal of this research was to evaluate the dynamics of ubiquitin-protein conjugate
populations in response to treatment with inhibitors of the ubiquitin-proteasome pathway …
populations in response to treatment with inhibitors of the ubiquitin-proteasome pathway …
[引用][C] The Relationship between P-glycoprotein, Carbonic Anhydrase XII, and the Thioredoxin System in Bortezomib Resistant Multiple Myeloma Cells
Y Zhang - 2019